API | eftilagimod alpha

eftilagimod alpha Report issue

Biologics Recombinant protein Experimental

Active Ingredient History

NOW

Eftilagimod alpha is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings:as adjuvant to cancer vaccines as first-line 'chemo-immunotherapy,' that is, combined with standard chemotherapy in combination immunotherapy with PD-1 treatments ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
- Lymphocyte activation gene 3 protein (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Breast Neoplasms (Phase 2/Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue